Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of seven systematic review(s)/meta-analysis(es). ^[1-7]
• Infective Endocarditis (IE): Dalbavancin achieved a clinical failure rate below 10% in five out of nine studies, with coagulase-negative Staphylococci as the most common pathogen (30.1%) and native valve endocarditis observed most frequently (48.7%).
• Osteoarticular (OA) Infections: An overall success rate of 79.3% was reported for dalbavancin in treating OA infections, with the highest success (92.3%) among patients receiving a three-dose regimen. Staphylococcus aureus was the most commonly isolated pathogen (67.5%).
• Gram-Positive Bacterial Infections and CRBSIs: Dalbavancin demonstrated effectiveness comparable to vancomycin for osteomyelitis, with superior outcomes in bacteremia, and was effective in catheter-related bloodstream infections (CRBSIs) and osteomyelitis within the Gram-positive infection category.
• General Safety Across Infections: Dalbavancin exhibited a favorable safety profile in treating infective endocarditis (IE), osteoarticular (OA) infections, and multi-drug-resistant (MDR) infections in newborns, with no significant safety concerns documented across different age cohorts and infection types.
• Comparative Safety in Gram-Positive Infections: For gram-positive bacterial infections, dalbavancin and oritavancin had fewer adverse events compared to vancomycin, particularly with a dual-dose regimen showing reduced adverse events (AEs) and adverse drug reactions (ADRs) compared to a single-dose regimen.
• There is no population types or subgroups information available in the reviewed studies.